0
0
0
0
1
2
3
$0
Is Zimmer Biomet solid or fragile? The Finex Financial Health Scanner reads ZBH's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $8.2B |
|---|---|
| Net income | $705.1M |
| Operating margin | 13.3% |
| Net margin | 8.6% |
| Cash and investments | $591.9M |
| Total debt | $7.5B |
| Free cash flow | $1.4B |
| Revenue growth (1 year) | 7.2% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.